The TRACK-TBI NETWORK has partnered with Abbott to test its prototype TBI point-of-care device. The i-STAT handheld blood analyzer and blood test under development can be used at the patient’s bedside to detect elevated levels of TBI biomarkers like GFAP and UCHL-1. To date, the study has enrolled more that 1,000 participants across the network. Participants have been enrolled that present with a suspected TBI (according to ACRM criteria) within 12 hours of injury and who have a CT scan ordered. A blood draw is collected 12 hours and within 12-24 hours coupled various outcome assessments at enrollment, and a full outcome battery at 2 weeks, 6 weeks, 3 months, and 6 month. There study also includes an MRI and an additional blood draw at 2 weeks and 6 months.